Argyria attributed to silvadene application in a patient with dystrophic epidermolysis bullosa

John C Browning; Moise L Levy

Argyria attributed to silvadene application in a patient with dystrophic epidermolysis bullosa

Dermatol Online J. 2008 Apr 15;14(4):9.

Authors

John C Browning¹, Moise L Levy

Affiliation

¹ Department of Dermatology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA. [email protected]

PMID: 18627731

Abstract

Argyria is most commonly reported in association with prolonged ingestion of silver-containing medicaments. This case illustrates the rather unique case of development of argyria following application of silver sulfadiazine in a patient with epidermolysis bullosa.

Publication types

Case Reports

MeSH terms

Administration, Cutaneous
Adult
Anti-Infective Agents, Local / administration & dosage
Anti-Infective Agents, Local / adverse effects*
Argyria / blood
Argyria / etiology*
Argyria / pathology
Epidermolysis Bullosa Dystrophica / drug therapy*
Epidermolysis Bullosa Dystrophica / pathology
Female
Humans
Male
Middle Aged
Risk Factors
Silver / blood*
Silver Sulfadiazine / administration & dosage
Silver Sulfadiazine / adverse effects*
Skin / pathology
Skin Absorption

Substances

Anti-Infective Agents, Local
Silver
Silver Sulfadiazine